Glofitamab/Polatuzumab Vedotin Exhibits Response Durability in R/R LBCL
The glofitamab-based regimen displayed manageable safety, with minimal high-grade CRS and infrequent low-grade ICANS in relapsed/refractory LBCL.
How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap
Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.
Zurletrectinib Generates Responses in Advanced NTRK Fusion Solid Tumors
No dose-limiting toxicities were observed in the phase 1/2 trial evaluating zurletrectinib in patients with NTRK/ROS1-driven malignancies.
What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss
Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.
Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome
Vickie Baracos, PhD, discusses recent results that investigate cancer cachexia and how the RNome of the muscle plays a role.
BL-B01D1 Shows Preliminary Efficacy, Favorable Safety in Urothelial Cancer
Among patients with locally advanced/metastatic urothelial cancer who received at least one 2.2 mg/kg dose of BL-B01D1, the confirmed ORR was 44.1%.
